Syndecan-1 in B lymphoid malignancies

Annals of Hematology

Volumn 81, Issue 3, 2002, Pages 125-135

  Sanderson, Ralph D ^a,b   Borset M ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Cancer; Heparan sulfate; Hepatocyte growth factor; Myeloma; Syndecan

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; HEPARAN SULFATE; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEOGLYCAN; SCATTER FACTOR; SYNDECAN 1;

ANGIOGENESIS; B LYMPHOCYTE; CANCER GROWTH; CELL ADHESION; CELL FUNCTION; CELL SURFACE; CONTROLLED STUDY; EFFECTOR CELL; EPITHELIUM; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SOLUBILITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; B-LYMPHOCYTES; HUMANS; LYMPHOMA; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; PROTEOGLYCANS; SYNDECAN-1; SYNDECANS;

EID: 0036941575     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0437-8     Document Type: Review

References (117)

1. Gallagher JT (2001) Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 108:357-361
2. Carey DJ (1997) Syndecans: multifunctional cell-surface coreceptors. Biochem J 327:1-16
3. Oh ES, Woods A, Couchman JR (1997) Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C. J Biol Chem 272:8133-8136
4. Reiland J, Ott VL, Lebakken CS, Yeaman C, McCarthy J, Rapraeger AC (1996) Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1. Biochem J 319:39-47
5. Rapraeger AC (1993) The coordinated regulation of heparan sulfate, syndecans and cell behavior. Curr Opin Cell Biol 5:844-853
6. Tanaka Y, Kimata K, Adams DH, Eto S (1998) Modulation of cytokine function by heparan sulfate proteoglycans: sophisticated models for the regulation of cellular responses to cytokines. Proc Assoc Am Physicians 110:118-125
7. Sanderson RD, Lalor P, Bernfield M (1989) B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1:27-35
8. Lalor P, Nossal GJV, Sanderson RD, McHeyzer-Williams MG (1992) Functional and molecular characterisation of single, (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific, IgG1+B cells from antibody-secreting and memory B cell pathways in the C57BL/6 immune response to NP. Eur J Immunol 22:3001-3011
9. Inki P, Jalkanen M (1996) The role of syndecan-1 in malignancies. Ann Med 28:63-67
10. Leppa S, Harkonen P, Jalkanen M (1991) Steroid-induced epithelial-fibroblastic conversion associated with syndecan suppression in S115 mouse mammary tumor cells. Cell Regul 2:1-11
11. Leppa S, Mali M, Miettinen HM, Jalkanen M (1992) Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells. Proc Natl Acad Sci USA 89:932-936
12. Kato M, Saunders S, Nguyen H, Bernfield M (1995) Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 6:559-576
13. Inki P, Joensuu H, Grenman R, Klemi P, Jalkanen M (1994) Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 70:319-323
14. Pulkkinen JO, Penttinen M, Jalkanen M, Klemi P, Grenman R (1997) Syndecan-1 - a new prognostic marker in laryngeal cancer. Acta Otolaryngol 117:312-315
15. Mali M, Andtfolk H, Miettinen HM, Jalkanen M (1994) Suppression of tumor cell growth by syndecan-1 ectodomain. J Biol Chem 269:27795-27798
16. Naka D, Ishii T, Shimomura T, Hishida T, Hara H (1993) Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes. Exp Cell Res 209:317-324
17. Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG (1995) Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Grow Fact Res 6:503-512
18. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S, Bernfield M (2000) Syndecan-1 is required for wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25:329-332
19. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, Buchler MW (2000) Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 88:12-20
20. Hayashi K, Hayashi M, Jalkanen M, Firestone JH, Trelstad RL, Bernfield M (1987) Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J Histochem Cytochem 35:1079-1088
21. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD (1993) Expression of syndecan regulates human myeloma plasma cell adhesion to type 1 collagen. Blood 81:767-774
22. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94:318-323
23. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS (2001) Syndecan-1 (cd138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14:1052-1058
24. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, Wijdenes J, Brochier J, Klein B (1998) The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 100:637-646
25. Witzig TE, Kimlinger T, Stenson M, Therneau T (1998) Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 31:167-175
26. Ihrcke NS, Platt JL (1996) Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol 168:625-637
27. Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD (2000) Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 96:2528-2536
28. Sanchez-Madrid F, del Pozo MA (1999) Leukocyte polarization in cell migration and immune interactions. EMBO J 18:501-511
29. Stanley MJ, Liebersbach BF, Liu W, Anhalt DJ, Sanderson RD (1995) Heparan sulfate-mediated cell aggregation: syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells. J Biol Chem 270:5077-5083
30. Carbone A, Gloghini A, Gattei V, Degan M, Improta S, Aldinucci D, Canzonieri V, Perin T, Volpe R, Gaidano G, Zagonel V, Pinto A (1997) Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood 89:3787-3794
31. Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V, Tirelli U, Dalla-Favera R, Gaidano G (2001) Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 97:744-751
32. Sebestyen A, Kovalszky I, Mihalik R, Gallai M, Bocsi J, Laszlo E, Benedek S, Sreter L, Kopper L (1997) Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia. Eur J Cancer 33:2273-2277
33. Sebestyen A, Berczi L, Mihalik R, Paku S, Matolcsy A, Kopper L (1999) Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. Br J Haematol 104:412-419
34. Sutcliffe M, Oscier D, Wright DH (2000) Syndecan-1 (CD138) expression in human non-Hodgkin's lymphomas. Br J Haematol 110:239-240
35. Borset M, Helseth E, Naume B, Wagge A (1993) Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol 85:446-451
36. Sun RX, Lu ZY, Wijdenes J, Brochier J, Hertog C, Rossi JF, Klein B (1997) Large scale and clinical grade purification of syndecan-1 + malignant plasma cells. J Immunol Methods 205:73-79
37. Zhan F, Hardin J, Kordsmeir B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fasses A, Crowley J, Tricot G, Barlogie B, Shaughnessy J (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1751
38. Draube A, Pfister R, Vockerodt M, Schuster S, Kube D, Diehl V, Tesch H (2001) Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Ann Hematol 80:83-89
39. Post J, Vooijs WC, Bast BJ, De Gast GC (1999) Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells. Int J Cancer 83:571-576
40. Ragnarsson L, Stromberg T, Wijdenes J, Totterman TH, Weigelt C (2001) Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells. Cancer Immunol Immunother 50:382-390
41. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148:811-824
42. Holen I, Drury NL, Hargreaves PG, Croucher PI (2001) Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells. Br J Haematol 114:414-421
43. Kainulainen V, Wang H, Schick C, Bernfield M (1998) Syndecans, heparan sulfate proteoglyeans, maintain the proteolytic balance of acute wound fluids. J Biol Chem 273:11563-11569
44. Dhodapkar MV, Kelly T, Theus A, Athotha AP, Barlogie B, Sanderson RD (1997) Elevated levels of shed syndecan-1 correlate with tumor mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Hematol 99:368-371
45. Klein B, Li XY, Lu ZY, Jourdan M, Tarte K, Brochier J, Claret E, Wijdenes J, Rossi JF (1999) Activation molecules on human myeloma cells. Curr Top Microbiol Immunol 246:335-341
46. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, Borset M (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95:388-392
47. Sanderson RD, Sneed TB, Young LA, Sullivan GL, Lander AD (1992) Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by the integral membrane proteoglycan, syndecan. J Immunol 148:3902-3911
48. Liebersbach BF, Sanderson RD (1994) Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269:20013-20019
49. Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, Klein B, Brochier J (1999) The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol 30:1405-1411
50. Chilosi M, Adami F, Lestani M, Montagna L, Cimarosto L, Semenzato G, Pizzolo G, Menestrina F (1999) CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 12:1101-1106
51. Lacy HM, Sanderson RD (2001) Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion. Blood 98:2160-2165
52. Wen Y, Richardson RT, Widgren EE, O'Rand MG (2001) Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J 357:25-31
53. Liu W, Litwack ED, Stanley MJ, Langford JK, Lander AD, Sanderson RD (1998) Heparan sulfate proteoglycans as adhesive and anti-invasive molecules: syndecans and glypican have distinct functions. J Biol Chem 273:22825-22832
54. Langford JK, Stanley MJ, Cao D, Sanderson RD (1998) Multiple heparan sulfate chains are required for optimal syndecan-1 function. J Biol Chem 273:29965-29971
55. Zhang L, David G, Esko JD (1995) Repetitive Ser-Gly sequences enhance heparan sulfate assembly in proteoglycans. J Biol Chem 270:27127-27135
56. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777
57. Dhodapkar MV, Abe EA, Theus A, Lacy M, Langford JK, Barlogie B, Sanderson RD (1998) Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth and bone cell differentiation. Blood 91:2679-2688
58. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC (1997) The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90:754-765
59. Yaccoby S, Barlogie B, Epstein J (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92:2908-2913
60. Yang Y, Yaccoby S, Epstein J, Sanderson RD (2001) Soluble syndecan-1 ectodomain promotes growth and dissemination of myeloma cells. Blood 98:637a
61. Perrimon N, Bernfield M (2000) Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404:725-728
62. Rapraeger AC, Krufka A, Olwin BB (1991) Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252:1705-1708
63. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848
64. Zioncheck TF, Richardson L, Liu J, Chang L, King KL, Bennett GL, Fugedi P, Chamow SM, Schwall RH, Stack RJ (1995) Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem 270:16871-16878
65. Tessler S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, Lemischka IR, Neufeld G (1994) Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem 269:12456-12461
66. Blanquaert F, Barritault D, Caruelle JP (1999) Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression. J Biomed Mater Res 44:63-72
67. Mummery RS, Rider CC (2000) Characterization of the heparin-binding properties of IL-6. J Immunol 165:5671-5679
68. Salek-Ardakani S, Arrand JR, Shaw D, Mackett M (2000) Heparin and heparan sulfate bind interleukin-10 and modulate its activity. Blood 96:1879-1888
69. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM (1996) Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A 93:13931-13936
70. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL (1997) Frequent translocation t(4;14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264
71. Saksela O, Moscatelli D, Sommer A, Rifkin DB (1988) Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107:743-751
72. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I (1994) Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 79:1015-1024
73. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL (1993) An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 259:1918-1921
74. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M (1999) Structural basis for FGF receptor dimerization and activation. Cell 98:641-650
75. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M (2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6:743-750
76. Kan M, Wang F, To B, Gabriel JL, McKeehan WL (1996) Divalent cations and heparin/heparan sulfate cooperate to control assembly and activity of the fibroblast growth factor receptor complex. J Biol Chem 271:26143-26148
77. Kan M, Wu X, Wang F, McKeehan WL (1999) Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 274:15947-15952
78. Nurcombe V, Ford MD, Wildschut JA, Bartlett PF (1993) Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 260:103-106
79. Gallagher JT (1997) Structure-activity relationship of heparan sulphate. Biochem Soc Trans 25:1206-1209
80. Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE (1994) Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269:18881-18890
81. Sanderson RD, Turnbull JE, Gallagher JT, Lander AD (1994) Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J Biol Chem 269:13100-13106
82. Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, Ornitz DM, Bernfield M (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4:691-697
83. Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, Sanderson RD, Waage A, Sundan A (2000) High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96:3139-3146
84. McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, Tufaro F (1998) The putative tumour suppressor EXT1 alters the expression of cell- surface heparan sulfate. Nat Genet 19:158-161
85. Wu X, Kan M, Wang F, Jin C, Yu C, McKeehan WL (2001) A rare premalignant prostate tumor epithelial cell syndecan-1 forms a fibroblast growth factor-binding complex with progression-promoting ectopic fibroblast growth factor receptor 1. Cancer Res 61:5295-5302
86. Sergeant N, Lyon M, Rudland PS, Fernig DG, Delehedde M (2000) Stimulation of DNA synthesis and cell proliferation of human mammary myoepithelial-like cells by hepatocyte growth factor/scatter factor depends on heparan sulfate proteoglycans and sustained phosphorylation of mitogen-activated protein kinases p42/44. J Biol Chem 275:17094-17099
87. Sakata H, Stahl SJ, Taylor WG, Rosenberg JM, Sakaguchi K, Wingfield PT, Rubin JS (1997) Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for Met binding and signaling. J Biol Chem 272:9457-9463
88. Rubin JS, Day RM, Breckenridge D, Atabey N, Taylor WG, Stahl SJ, Wingfield PT, Kaufman JD, Schwall R, Bottaro DP (2001) Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling. J Biol Chem 276:32977-32983
89. Schwall RH, Chang LY, Godowski PJ, Kahn DW, Hillan KJ, Bauer KD, Zioncheck TF (1996) Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J Cell Biol 133:709-718
90. Borset M, Hjorthhansen H, Seidel C, Sundan A, Waage A (1996) Hepatocyte growth factor and its receptor c-Met in multiple myeloma. Blood 88:3998-4004
91. Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A (1996) Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 271:24655-24661
92. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A (1998) Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 91:806-812
93. Derksen PWB, Keehnen RMJ, Evers LM, van Oers MHJ, Spaargaren M, Pals ST (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes met signaling in multiple myeloma. Blood 99:1405-1410
94. Gomez-Mouton C, Abad JL, Mira E, Lacalle RA, Gallardo E, Jimenez-Baranda S, Illa I, Bernad A, Manes S, Martinez AC (2001) Segregation of leading-edge and uropod components into specific lipid rafts during T cell polarization. Proc Natl Acad Sci U S A 98:9642-9647
95. Galbiati F, Razani B, Lisanti MP (2001) Emerging themes in lipid rafts and caveolae. Cell 106:403-411
96. Treon SP, Anderson KC (1998) Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Hematol 5:42-48
97. Jelinek DF (1999) Mechanisms of myeloma cell growth control. Hematol Oncol Clin North Am 13:1145-1157
98. Sakou T (1998) Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 22:591-603
99. Reddi AH (1992) Regulation of cartilage and bone differentiation by bone morphogenetic proteins. Curr Opin Cell Biol 4:850-855
100. Hjertner O, Hjorth-Hansen H, Borset M, Seidel C, Waage A, Sundan A (2001) Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 97:516-522
101. Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, Koseki T, Nishihara T, Ikeda Y (2000) Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 96:2005-2011
102. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
103. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518-527
104. Feuerherm AJ, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M, Faxvaag A (2001) Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 30:229-234
105. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nielsen JL, Hjorth-Hansen H, Waage A, Sundan A, Borset M (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98:2269-2271
106. Fuki IV, Kuhn KM, Lomazov IR, Rothman VL, Tuszynski GP, Iozzo RV, Swenson TL, Fisher EA, Williams KJ (1997) The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 100:1611-1622
107. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98:11581-11586
108. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87:503-508
109. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064-3073
110. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
111. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R (2000) Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85:800-805
112. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, Morgan GJ (1997) Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 97:46-55
113. Carbone A, Gloghini A, Gaidano G, Franceschi S, Capello D, Drexler HG, Falini B, Dalla-Favera R (1998) Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 92:2220-2228
114. Gaidano G, Gloghini A, Gattei V, Rossi MF, Cilia AM, Godeas C, Degan M, Perin T, Canzonieri V, Aldinucci D, Saglio G, Carbone A, Pinto A (1997) Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood 90:4894-4900
115. Carbone A, Gaidano G, Gloghini A, Larocca LM, Capello D, Canzonieri V, Antinori A, Tirelli U, Falini B, Dalla-Favera R (1998) Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non- Hodgkin's lymphomas. Blood 91:747-755
116. Gattei V, Godeas C, Degan M, Rossi FM, Aldinucci D, Pinto A (1999) Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. Br J Haematol 104:152-162
117. Carbone A, Gloghini A, Larocca LM, Antinori A, Falini B, Tirelli U, Dalla-Favera R, Gaidano G (1999) Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 93:2319-2326